EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression

Richard C Shelton, Robert E Litman, Howard Hassman, David P Walling, Salvador Ros Montalbán, Joan Salvà-Coll, John Zajecka, Oleksandr Sverdlov, Baltazar Gomez-Mancilla, Mark P Healy, Y Gopi Shanker, Maria Berkheimer und 5 weitere

The Journal of Clinical Psychiatry · 06.08.2025 · 86 (3)

DOI: 10.4088/jcp.23m15246 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Psychiatry, online erschienen am 06.08.2025. Verfasst von Richard C Shelton und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Neurobiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. Hauptthemen laut MEDLINE: Depressive Disorder, Treatment-Resistant, Piperidines, Receptors, N-Methyl-D-Aspartate, Major Depressive Disorder. Die Arbeit wurde bisher 6-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Onfasprodil (MIJ821) is a highly potent and novel selective NR2B subunit negative allosteric modulator. This phase 2, randomized, placebo-controlled, proof-of-concept study evaluated efficacy and safety of onfasprodil in patients with treatment-resistant major depression (TRD).

Methods

Adults with TRD who did not respond to ≥2 antidepressants were randomized (3:3:3:3:6:4) to receive a 40-minute intravenous infusion of onfasprodil 0.16 mg/kg weekly (n = 11), onfasprodil 0.16 mg/kg biweekly (n = 10), onfasprodil 0.32 mg/kg weekly (n = 10), onfasprodil 0.32 mg/kg biweekly (n = 9), placebo weekly (n=20), or ketamine 0.5 mg/kg weekly (n= 10) for 6 weeks. Primary end point was change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) score at 24 hours. Secondary end points were change in MADRS score at 48 hours and at final follow-up at 6 weeks. Safety and tolerability were assessed during the study.

Results

Of 70 randomized patients, 53 (75.7%) completed the study. At 24 hours, adjusted mean differences versus placebo for pooled onfasprodil 0.16 mg/kg, 0.32 mg/kg, and ketamine groups were -8.25 (P = .001), -5.71 (P = .019), and -5.67 (P = .046), and at 48 hours, -7.06 (P = .013), -7.37 (P = .013), and -11.02 (P = .019), respectively. At Week 6, adjusted arithmetic mean MADRS difference between ketamine and placebo was -5.24 (80% CI, -10.42 to -0.06; P= .0974). At Week 6, the difference versus placebo on MADRS was -5.78 (P= .0427) for pooled 0.16 mg/kg and -4.24 (P= .1133) for pooled 0.32 mg/kg groups. The commonest treatment-emergent adverse events in the onfasprodil groups were dizziness (14.3%), transient amnesia (14.3%), and somnolence (11.4%). It had overall a good safety profile and was well tolerated.

Conclusion

Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to be maintained at Week 6, particularly for the lower-dose group. Trial Registration: ClinicalTrials.gov identifier: NCT03756129.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Depressive Disorder, Treatment-ResistantPiperidinesReceptors, N-Methyl-D-AspartateMajor Depressive DisorderHumansMaleFemaleMiddle AgedAdultProof of Concept StudyKetamineTreatment OutcomeDouble-Blind MethodAntidepressive AgentsAllosteric Regulation

Substanzen

PiperidinesReceptors, N-Methyl-D-AspartateNR2B NMDA receptorKetamineAntidepressive Agentsifenprodil

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Neurobiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
  • Georgetown University Medical School, Washington, DC.
  • Hassman Research Institute, Marlton, New Jersey.
  • Collaborative Neuroscience Network Garden Grove, Garden Grove, California.
  • Instituto Internacional de Neurociencias Aplicadas Barcelona, Barcelona, Spain.
  • Hospital Universitari Son Espases, Servicio de Psiquiatría, UIB, IdISBa, Palma de Mallorca, Spain.

Zitieren

APA

Shelton, R. C., Litman, R. E., Hassman, H., Walling, D. P., Ros Montalbán, S., Salvà-Coll, J., Zajecka, J., Sverdlov, O., Gomez-Mancilla, B., Healy, M. P., Shanker, Y. G., Berkheimer, M., Faller, T., von Raison, F., Serban, C., Cha, J. H., & Ghaemi, S. N. (2025). Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression. The Journal of Clinical Psychiatry, 86(3). https://doi.org/10.4088/jcp.23m15246

Vancouver

Shelton RC, Litman RE, Hassman H, Walling DP, Ros Montalbán S, Salvà-Coll J, et al. Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression. The Journal of Clinical Psychiatry. 2025;86(3). doi:10.4088/jcp.23m15246

BibTeX
@article{Shelton2025,
  author = {Shelton, Richard C and Litman, Robert E and Hassman, Howard and Walling, David P and Ros Montalbán, Salvador and Salvà-Coll, Joan and Zajecka, John and Sverdlov, Oleksandr and Gomez-Mancilla, Baltazar and Healy, Mark P and Shanker, Y Gopi and Berkheimer, Maria and Faller, Thomas and von Raison, Florian and Serban, Carmen and Cha, Jang-Ho and Ghaemi, S Nassir},
  title = {Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression},
  journal = {The Journal of Clinical Psychiatry},
  year = {2025},
  volume = {86},
  number = {3},
  doi = {10.4088/jcp.23m15246}
}
Kostenlos starten →